Transition Therapeutics (NASDAQ: TTHI) and KalVista Pharmaceuticals (NASDAQ:KALV) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
75.6% of KalVista Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Transition Therapeutics and KalVista Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$1.50 million||69.26||-$18.60 million||N/A||N/A|
Transition Therapeutics has higher revenue, but lower earnings than KalVista Pharmaceuticals.
This is a breakdown of recent ratings and target prices for Transition Therapeutics and KalVista Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KalVista Pharmaceuticals has a consensus price target of $27.00, suggesting a potential upside of 152.34%. Given KalVista Pharmaceuticals’ higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Transition Therapeutics.
This table compares Transition Therapeutics and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
KalVista Pharmaceuticals beats Transition Therapeutics on 5 of the 8 factors compared between the two stocks.
Transition Therapeutics Company Profile
Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company’s principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company’s technologies are focused on the treatment of agitation and aggression in Alzheimer’s disease and diabetes. The Company’s subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company’s subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company’s other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Receive News & Ratings for Transition Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transition Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.